Ventricular Progenitor Cell Differentiation Protocol for Heart Failure

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for heart failure (HF) are limited, with high mortality rates and a lack of effective options for advanced HF patients, despite the use of pharmacological therapies and devices.

Innovation Solution

A new protocol for ventricular progenitor cell differentiation is developed, which reduces the risk of teratoma formation and produces a cell population suitable for use as a cell therapy product for treating heart failure. This protocol involves specific stages of cell culture and sorting to deplete pluripotent cells, resulting in a cell population with at least 70% cardiac progenitor cell-associated markers and less than 1% OCT4-expressing cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If pluripotent stem cells are used for cardiac tissue regeneration, then the potential for differentiation into cardiac tissue is improved, but the risk of teratoma formation increases

Engineering Contradiction:

Improvedifferentiation potentialVSAvoidteratoma formation risk

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes pluripotent cells from the cell population through specific sorting methods (such as FACS or magnetic sorting) to eliminate the harmful teratoma formation risk while preserving the beneficial cardiac progenitor cells that can differentiate into cardiac tissue

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent performs preliminary differentiation of pluripotent stem cells into cardiac progenitor cells before transplantation, and conducts preliminary sorting to remove remaining pluripotent cells, thereby preventing teratoma formation while maintaining cardiac regeneration potential

Inventive Principle:

Principle #10Preliminary action

2Reliability

If cell sorting is performed to remove pluripotent cells, then the safety of cell therapy is improved, but the complexity of the manufacturing process increases

Engineering Contradiction:

Improvecell therapy safetyVSAvoidmanufacturing process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces complex manual sorting procedures with automated cell sorting technologies such as fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS), which use fluorescent markers or magnetic beads to automatically separate pluripotent cells from cardiac progenitor cells, thereby improving safety while managing manufacturing complexity through automation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20250161368A1Cell Therapy

Publication Date: 2025.05.22 ASTRAZENECA AB

AI summary

Populations of cells for use in the treatment of heart disease and methods of making the same.